CLCN1 is a human gene whose product CLC-1 is a homodimeric voltage-gated chloride channel belonging to the CLC chloride channel family. Variants in CLCN1 have been implicated in neurodegeneration and neuromuscular diseases. This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration. [1]
CLC-1 is a voltage-gated chloride channel primarily expressed in skeletal muscle, where it stabilizes the resting membrane potential and facilitates normal muscle excitability. It is encoded by the CLCN1 gene. [2]
| Gene Symbol | CLCN1 |
| Gene Name | Chloride Voltage-Gated Channel 1 |
| Chromosome | 7q34 |
| NCBI Gene ID | 1187 |
| OMIM | 118425 |
| Ensembl ID | ENSG00000100137 |
| UniProt ID | P35523 |
| Protein Class | Voltage-gated chloride channel |
| Associated Diseases | Myotonia Congenita, Neuromuscular Disorders |
CLC-1 is a homodimeric voltage-gated chloride channel belonging to the CLC chloride channel family. [3]
| Tissue | Expression Level | Functional Significance |
|---|---|---|
| Skeletal muscle (type I) | High | Primary site for myotonia pathophysiology |
| Skeletal muscle (type II) | High | Endurance fiber function |
| Cardiac muscle | Moderate | Cardiac excitability |
| Brain (cortex) | Low | Neuronal chloride homeostasis |
| Brain (cerebellum) | Low | Motor coordination potential |
The CLCN gene family includes 9 members in humans:
| Channel | Tissue Distribution | Associated Diseases |
|---|---|---|
| CLCN1 | Skeletal muscle | Myotonia congenita |
| CLCN2 | Brain, kidney | Leukemia, blindness |
| CLCN3-7 | Various | Neurodegeneration, storage diseases |
| CLCN7 | Bone, lysosomes | Osteopetrosis |
| CLCN-Kb | Kidney | Bartter syndrome |
CLC-1 shares significant structural features with other CLC channels:
CLC-1 is a homodimeric voltage-gated chloride channel with two independent pores, each formed by a single subunit. Each subunit contains 18 transmembrane domains organized into a unique dimeric architecture[3:1]. The channel exhibits:
The channel exhibits complex gating behavior:
Key pharmacological agents affecting CLC-1:
| Agent | Effect | Clinical Relevance |
|---|---|---|
| Flecainide | Open state stabilizer | Investigated for myotonia |
| Ranolazine | Partial inhibitor | May reduce muscle excitability |
| 9-anthracene carboxylic acid | Blocker | Research tool |
Both recessive (Thomsen) and dominant (Becker) forms result from CLCN1 mutations:
Recessive mutations: Usually null or severe loss-of-function alleles
Dominant mutations: Usually gain-of-function or dominant-negative
The mechanism of myotonia in CLCN1 mutations:
| Mutation Type | Severity | Onset | Common Variants |
|---|---|---|---|
| Null/Null | Severe | Neonatal | Frameshift, nonsense |
| Null/Missense | Moderate | Childhood | Missense + null |
| Dominant | Variable | Variable | Missense dominant |
CLCN1-related disorders share features with other channelopathies:
While CLCN1 is primarily a muscle channel, general principles of ion channel dysfunction apply to Alzheimer's disease and Parkinson's disease[@chen2020]:
Patients with neurodegenerative diseases often experience muscle dysfunction:
Understanding ion channel function in muscle provides insights into these broader phenomena.
Current and emerging treatments for CLCN1-related disorders:
Sodium channel blockers: Reduce sodium influx to compensate for reduced chloride
Chloride channel openers: Enhance remaining channel function
Gene therapy: Viral vector delivery of wild-type CLCN1
Antisense oligonucleotides: Nonsense suppression approaches
Small molecule correctors: Compounds that restore channel trafficking
Additional evidence sources: [4]
Emerging research suggests CLCN1 and other chloride channels may play roles in AD pathogenesis:
While primarily a muscle channel, CLCN1 connections to PD include:
The CLC-1 pore architecture includes:
The channel exhibits multiple gating modes:
| Mechanism | Effect | Modulators |
|---|---|---|
| Phosphorylation | Altered gating | PKC, PKA |
| pH regulation | pH-sensitive gating | Intracellular protons |
| Calcium | Modulation | Calmodulin binding |
| Proteolysis | Channel cleavage | Caspases |
Key models for studying CLCN1:
CLCN1 encodes CLC-1, a voltage-gated chloride channel critical for skeletal muscle excitability. While primarily associated with myotonia congenita, understanding CLC-1 function provides insights into ion channel dysfunction in neurodegenerative diseases. The channel's unique dimeric structure, complex gating mechanisms, and disease-causing mutations make it an important research target for both neuromuscular and neurodegenerative conditions.
Steinmeyer et al. Structure and function of CLC-1 chloride channel (1991). 1991. ↩︎
Koch et al. CLC-1 mutations cause myotonia congenita (1992). 1992. ↩︎
Jentsch et al. Molecular physiology of CLC chloride channels (2002). 2002. ↩︎ ↩︎
Puig et al. CLC-1 channel gating and modulation (2007). 2007. ↩︎